Nuformix Regulatory News (NFX)

Nuformix plc

("Nuformix" or "the Company")

Update re: Broker

Nuformix (LSE: NFX.L), the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, notes the announcement today regarding the Company's broker Beaufort Securities Limited ("BSL") being placed into insolvency and that the Financial Conduct Authority (the "FCA") has imposed requirements on BSL to cease all regulatory activity. As a result BSL will no longer be able to provide broking services to the Company and the Board is therefore looking to make a new appointment of a broker to the Company in due course.  

Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L. Follow Nuformix on Vox Markets: follow at: www.voxmarkets.co.uk/company/NFX

and the Company's web site at: www.nuformix.com

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

ENDS

Enquiries:

About Nuformix plc www.nuformix.com 

Nuformix is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs. Nuformix' risk-mitigated development strategy has resulted in a pipeline of discoveries through which it has developed and patented novel cocrystal forms of approved small molecules.

Nuformix has created an IP portfolio containing a range of granted patents covering cocrystal forms of five small molecule drugs. Nuformix is targeting high-value unmet needs with its lead programmes in oncology supportive care: NXP001 and fibrosis: NXP002.

Nuformix was established in Cambridge in 2008 and has invested into pharmaceutical cocrystal R&D, establishing world-class capability and know-how in cocrystal discovery and development, yielding multiple product opportunities. Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX.L.